A practical reference on GHRH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-03. Anything still debated is marked as such rather than presented as settled.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Owing to the rapid decline in the populations of the animals that produce it, the importation and sale of ivory in many countries is banned or severely restricted. In the ten years preceding a decision in 1989 by CITES to ban international trade in African elephant ivory, the population of African elephants declined from 1.3 million to around 600,000. It was found by investigators from the Environmental Investigation Agency (EIA) that CITES sales of stockpiles from Singapore and Burundi (270 tonnes and 89.5 tonnes respectively) had created a system that increased the value of ivory on the international market, thus rewarding international smugglers and giving them the ability to control the trade and continue smuggling new ivory. Since the ivory ban, some Southern African countries have claimed their elephant populations are stable or increasing, and argued that ivory sales would support their conservation efforts. Other African countries oppose this position, stating that renewed ivory trading puts their own elephant populations under greater threat from poachers reacting to demand. CITES allowed the sale of 49 tonnes of ivory from Zimbabwe, Namibia and Botswana in 1997 to Japan. In 2007, under pressure from the International Fund for Animal Welfare, eBay banned all international sales of elephant-ivory products. The decision came after several mass slaughters of African elephants, most notably the 2006 Zakouma elephant slaughter in Chad.
Protostomes and deuterostomes differ in several ways. Early in development, deuterostome embryos undergo radial cleavage during cell division, while many protostomes (the Spiralia) undergo spiral cleavage. Animals from both groups possess a complete digestive tract, but in protostomes the first opening of the embryonic gut develops into the mouth, and the anus forms secondarily. In deuterostomes, the anus forms first while the mouth develops secondarily. Most protostomes have schizocoelous development, where cells simply fill in the interior of the gastrula to form the mesoderm. In deuterostomes, the mesoderm forms by enterocoelic pouching, through invagination of the endoderm. The main deuterostome taxa are the Ambulacraria and the Chordata. Ambulacraria are exclusively marine and include acorn worms, starfish, sea urchins, and sea cucumbers. The chordates are dominated by the vertebrates (animals with backbones), which consist of fishes, amphibians, reptiles, birds, and mammals. The protostomes include the Ecdysozoa, named after their shared trait of ecdysis, growth by moulting, Among the largest ecdysozoan phyla are the arthropods and the nematodes. The rest of the protostomes are in the Spiralia, named for their pattern of developing by spiral cleavage in the early embryo. Major spiralian phyla include the annelids and molluscs.
Since this single emitted neutrino carries the entire decay energy, it has this single characteristic energy. Similarly, the momentum of the neutrino emission causes the daughter atom to recoil with a single characteristic momentum. The resulting daughter nuclide, if it is in an excited state, then transitions to its ground state. Usually, a gamma ray is emitted during this transition, but nuclear de-excitation may also take place by internal conversion. Following capture of an inner electron from the atom, an outer electron replaces the electron that was captured and one or more characteristic X-ray photons is emitted in this process. Electron capture sometimes also results in the Auger effect, where an electron is ejected from the atom's electron shell due to interactions between the atom's electrons in the process of seeking a lower energy electron state. Following electron capture, the atomic number is reduced by one, the neutron number is increased by one, and there is no change in mass number. Simple electron capture by itself results in a neutral atom, since the loss of the electron in the electron shell is balanced by a loss of positive nuclear charge. However, a positive atomic ion may result from further Auger electron emission. Electron capture is an example of weak interaction, one of the four fundamental forces.
=== Evaluating approaches to AI === No established unifying theory or paradigm has guided AI research for most of its history. The unprecedented success of statistical machine learning in the 2010s eclipsed all other approaches (so much so that some sources, especially in the business world, use the term "artificial intelligence" to mean "machine learning with neural networks"). This approach is mostly sub-symbolic, soft and narrow.
On 18 September, Donald Trump posted on Truth Social that the US, Denmark, and Greenland had agreed to a new security deal that addressed all of the US's concerns, and provided for a larger US military footprint. Trump claimed that the deal gives the US "permanent control" over security in Greenland, while officials from Denmark and Greenland said that the deal does not transfer sovereignty of Greenland to the US. Trump also said that his administration would begin cooperating with local authorities to maintain a "large Military presence in the appropriate part of Greenland, of which there are many." An anonymous State Department official said the deal would remain in effect even if Greenland became independent in the future, that it bans non-NATO states from maintaining a military presence in Greenland; bars investments in Greenland by Russia and China, and grants the US permanent rights to install military bases and use Greenland's airspace. US Secretary of State Marco Rubio said that the deal "permanently and completely addresses our national security concerns in Greenland" and described it as a "huge win for the United States and the American people." Danish Prime Minister Mette Frederiksen said the deal strengthens "security in the Arctic and the North Atlantic area" and that the deal would be signed at the upcoming United Nations General Assembly. She did not discuss specific policies and stressed that it required parliamentary approval to be enacted.
Sources: en.wikipedia.org
== Gland atrophy == The adrenal glands atrophy during prolonged use of exogenous glucocorticoids like prednisone. Atrophy of the breasts can occur with prolonged estrogen reduction, as with anorexia nervosa or menopause. Testicular atrophy can occur with prolonged use of enough exogenous sex steroids (either androgen or estrogen) to reduce gonadotropin secretion.
== History == Glycogen was discovered by Claude Bernard. His experiments showed that the liver contained a substance that could give rise to reducing sugar by the action of a "ferment" in the liver. By 1857, he described the isolation of a substance he called "la matière glycogène", or "sugar-forming substance". Soon after the discovery of glycogen in the liver, M.A. Sanson found that muscular tissue also contains glycogen. The empirical formula for glycogen of (C6H10O5)n was established by August Kekulé in 1858. Sanson, M. A. "Note sur la formation physiologique du sucre dans l’economie animale." Comptes rendus des séances de l'Académie des Sciences 44 (1857): 1323–5.
Penn Station does not have a unified design or floor plan but rather is divided into separate Amtrak, LIRR and NJ Transit concourses with each concourse maintained and styled differently by its respective operator. The Amtrak and NJ Transit concourses are located on the first level below the street level while the Long Island Rail Road concourse is two levels below street level. The layout has been called a "confusing, multilevel maze of corridors," even prompting Amtrak at one point to release an app to assist commuters in navigating the station. Platform widths vary, with eight of the 11 platforms in the range of 19–20 feet wide. Platform 6 is the narrowest, at 17 feet, while Platform 1 is slightly wider, at 22 feet. Platform 10 is the widest platform, used exclusively by LIRR and nominally 38 feet wide. The main concourse, which was principally used by Amtrak until the opening of the Moynihan Train Hall in 2021, is at the west end of the block directly beneath Madison Square Garden and now used principally by NJ Transit. It was created out of the original station's waiting rooms and main concourse, though few remnants of the original still exist in the space. It was renovated in the early 2000s in anticipation of Acela service and includes an enclosed waiting area for ticketed passengers with seats, outlets and Wi-Fi.
DNA damages are induced by reactive carbonyls, principally methylglyoxal and glyoxal, at a frequency similar to that of oxidative DNA damages. Such damage, referred to as DNA glycation, can cause mutation, breaks in DNA and cytotoxicity. In humans, a protein DJ-1 (also named PARK7), has a key role in the repair of glycated DNA bases.
Bacteria encode evolutionary predecessors of cGAS, called cGAS/DncV-like nucleotidyltransferases (CD-NTases), which detect bacteriophage infection and produce diverse nucleotide second messengers. The regulation of bacterial CD-NTase activation remains an open question. Recent research has shown that CD-NTase-associated protein 2 (Cap2) primes bacterial CD-NTases for activation through a ubiquitin transferase-like mechanism. A cryo-electron microscopy structure of the Cap2–CD-NTase complex reveals Cap2 as an all-in-one ubiquitin transferase-like protein, with distinct domains resembling eukaryotic E1 and E2 proteins. The structure captures a reactive-intermediate state with the CD-NTase C-terminus positioned in the Cap2 E1 active site and conjugated to AMP. Cap2 conjugates the CD-NTase C-terminus to a target molecule that primes the CD-NTase for increased cGAMP production. Additionally, a specific endopeptidase, Cap3, balances Cap2 activity by cleaving CD-NTase–target conjugates. This research demonstrates that bacteria control immune signaling using an ancient, minimized ubiquitin transferase-like system, providing insights into the evolution of E1 and E2 machinery across domains of life.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.